374 related articles for article (PubMed ID: 32188597)
1. Management of ANCA associated vasculitis.
Wallace ZS; Miloslavsky EM
BMJ; 2020 Mar; 368():m421. PubMed ID: 32188597
[TBL] [Abstract][Full Text] [Related]
2. Treatment Strategies in ANCA-Associated Vasculitis.
Emejuaiwe N
Curr Rheumatol Rep; 2019 May; 21(7):33. PubMed ID: 31123922
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission in Nonlife-Threatening Relapses of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Randomized, Controlled Trial.
Tuin J; Stassen PM; Bogdan DI; Broekroelofs J; van Paassen P; Cohen Tervaert JW; Sanders JS; Stegeman CA
Clin J Am Soc Nephrol; 2019 Jul; 14(7):1021-1028. PubMed ID: 31253599
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
[TBL] [Abstract][Full Text] [Related]
5. L52. Vasculitis treatment: is it time to change the standard of care for ANCA-associated vasculitis?
Hoffman GS
Presse Med; 2013 Apr; 42(4 Pt 2):643-50. PubMed ID: 23474045
[No Abstract] [Full Text] [Related]
6. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
[TBL] [Abstract][Full Text] [Related]
7. Hallmark trials in ANCA-associated vasculitis (AAV) for the pediatric rheumatologist.
Lee JJY; Alsaleem A; Chiang GPK; Limenis E; Sontichai W; Yeung RSM; Akikusa J; Laxer RM
Pediatr Rheumatol Online J; 2019 Jun; 17(1):31. PubMed ID: 31242923
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial.
Jones RB; Hiemstra TF; Ballarin J; Blockmans DE; Brogan P; Bruchfeld A; Cid MC; Dahlsveen K; de Zoysa J; Espigol-Frigolé G; Lanyon P; Peh CA; Tesar V; Vaglio A; Walsh M; Walsh D; Walters G; Harper L; Jayne D;
Ann Rheum Dis; 2019 Mar; 78(3):399-405. PubMed ID: 30612116
[TBL] [Abstract][Full Text] [Related]
9. Treatment of ANCA-associated vasculitis: new therapies and a look at old entities.
Zand L; Specks U; Sethi S; Fervenza FC
Adv Chronic Kidney Dis; 2014 Mar; 21(2):182-93. PubMed ID: 24602467
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of mycophenolate mofetil as a remission induction therapy in antineutrophil cytoplasmic antibody: associated vasculitis-a meta-analysis.
Kuzuya K; Morita T; Kumanogoh A
RMD Open; 2020 Apr; 6(1):. PubMed ID: 32371435
[TBL] [Abstract][Full Text] [Related]
11. [Diagnosis and management of small vessel vasculitides].
Pettersson T; Karjalainen A
Duodecim; 2010; 126(12):1496-507. PubMed ID: 20617753
[TBL] [Abstract][Full Text] [Related]
12. Impact of rituximab trials on the treatment of ANCA-associated vasculitis.
Alberici F; Jayne DR
Nephrol Dial Transplant; 2014 Jun; 29(6):1151-9. PubMed ID: 24126571
[TBL] [Abstract][Full Text] [Related]
13. Early Outcomes in Children With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Morishita KA; Moorthy LN; Lubieniecka JM; Twilt M; Yeung RSM; Toth MB; Shenoi S; Ristic G; Nielsen SM; Luqmani RA; Li SC; Lee T; Lawson EF; Kostik MM; Klein-Gitelman M; Huber AM; Hersh AO; Foell D; Elder ME; Eberhard BA; Dancey P; Charuvanij S; Benseler SM; Cabral DA;
Arthritis Rheumatol; 2017 Jul; 69(7):1470-1479. PubMed ID: 28371513
[TBL] [Abstract][Full Text] [Related]
14. Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis.
Jones RB
Nephron Clin Pract; 2014; 128(3-4):243-9. PubMed ID: 25401382
[TBL] [Abstract][Full Text] [Related]
15. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
Timlin H; Lee SM; Manno RL; Seo P; Geetha D
Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial.
Maritati F; Alberici F; Oliva E; Urban ML; Palmisano A; Santarsia F; Andrulli S; Pavone L; Pesci A; Grasselli C; Santi R; Tumiati B; Manenti L; Buzio C; Vaglio A
PLoS One; 2017; 12(10):e0185880. PubMed ID: 29016646
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive and cytotoxic therapy: pharmacology, toxicities, and monitoring.
Wang T; Weigt SS; Belperio JA; Lynch JP
Semin Respir Crit Care Med; 2011 Jun; 32(3):346-70. PubMed ID: 21674420
[TBL] [Abstract][Full Text] [Related]
18. Rituximab in ANCA-Associated Vasculitis.
Hassan RI; Gaffo AL
Curr Rheumatol Rep; 2017 Feb; 19(2):6. PubMed ID: 28155022
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive and glucocorticoid therapy for the treatment of ANCA-asssociated vasculitis.
Neumann I
Rheumatology (Oxford); 2020 May; 59(Suppl 3):iii60-iii67. PubMed ID: 32348519
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes in elderly patients with ANCA-associated vasculitis.
McGovern D; Williams SP; Parsons K; Farrah TE; Gallacher PJ; Miller-Hodges E; Kluth DC; Hunter RW; Dhaun N
Rheumatology (Oxford); 2020 May; 59(5):1076-1083. PubMed ID: 31794032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
